VIVA HEALTH is pleased to announce a partnership with CardioMEMS.

Cardiac hemodynamic monitoring in the management of heart failure using the implantable wireless pulmonary artery pressure monitor (CardioMEMS), may be considered medically necessary for members with NYHA functional Class III heart failure who have been hospitalized for heart failure in the previous year.

The effective date of this change is July 01, 2021 with a Prior Authorization required by VIVA HEALTH.

CardioMEMS™ HF System Food and Drug Administration (FDA) Indications and Usage:

The CardioMEMS™ HF System received FDA approval in May 2014 and is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in NYHA Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Background:

The CardioMEMS™ HF System is the first and only FDA-approved heart failure (HF) monitor proven to significantly reduce heart failure hospital admissions and improve quality of life in New York Heart Association (NYHA) class III patients. The CardioMEMS Heart Failure (HF) System is a wireless pulmonary arterial (PA) pressure monitoring system. It measures PA pressures from a battery free sensor in the distal pulmonary artery. An electronic system transmits the generated data to a secure network where it is available for the interpretation by the treating physician. The CardioMEMS (HF) System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

Thank you,

Tara M. Bryant, M.D., B.S.N.
Chief Medical Officer